Cargando…

Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets

Detalles Bibliográficos
Autor principal:	Kim, Jae Hak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Neurogastroenterology and Motility 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786092/ https://www.ncbi.nlm.nih.gov/pubmed/33380550 http://dx.doi.org/10.5056/jnm20260

Ejemplares similares

Efficacy and Safety of DWJ1252 Compared With Gasmotin in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study
por: Park, Jin Hwa, et al.
Publicado: (2021)

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
por: Kim, Yeon-Sook, et al.
Publicado: (2022)

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia
por: Irving, Gordon A, et al.
Publicado: (2012)

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
por: McClung, M. R., et al.
Publicado: (2011)

Personal dose-equivalent conversion coefficients for 1252 radionuclides
por: Otto, Thomas
Publicado: (2016)

Once upon a Time
Publicado: (2020)

Psycholinguistic and affective norms for 1,252 Spanish idiomatic expressions
por: Gavilán, José M., et al.
Publicado: (2021)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Initial genome sequencing of the sugarcane CP 96-1252 complex hybrid
por: Miller, Jason R., et al.
Publicado: (2017)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

A Highly Effective Bacteriophage-1252 to Control Multiple Serovars of Salmonella enterica
por: Tung, Chuan-Wei, et al.
Publicado: (2023)

Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Heterogenesis Once More
Publicado: (1904)

Vivisection Once More
Publicado: (1881)

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
por: Banevicius, Mary A, et al.
Publicado: (2013)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi, Alessandra, et al.
Publicado: (2013)

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
por: O’Byrne, Paul M., et al.
Publicado: (2016)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

P1252: PREDICTING THE RESPONSE OF DLBCL CELLS TO BH3-MIMETICS USING SYSTEMS BIOLOGY
por: Cloete, I., et al.
Publicado: (2022)

The Drink Question Once Again
Publicado: (1904)

Reciprocity in Licensure Once More
Publicado: (1903)

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
por: de Wit, R., et al.
Publicado: (1996)

Correction: Briggs, D.J.; Moore, S.M. The Route of Administration of Rabies Vaccines: Comparing the Data. Viruses 2021, 13, 1252
por: Briggs, Deborah J., et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Thyroxine for Thyroxine-Resistant Hypothyroidism
por: Jayakumari, Chellama, et al.
Publicado: (2019)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
por: Kim, Ju-Young, et al.
Publicado: (2015)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

The Different Roles of MET in the Development and Treatment of Cancer
por: Mollerup, Jens, et al.
Publicado: (2023)

1252. Penicillin Allergy Reassessment for Treatment Improvement (PARTI): A Dental Office Tool to Support Appropriate Penicillin Allergy Labeling
por: Coyne, Ashlan J Kunz, et al.
Publicado: (2023)

Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Monkeypox: A poxvirus emerges once again()
por: Ena, J., et al.
Publicado: (2022)

Preclinical characterization of the JAK/STAT inhibitor SGI-1252 on skeletal muscle function, morphology, and satellite cell content
por: Sorensen, Jacob R., et al.
Publicado: (2018)

1252. Development of a Surgical Site Infection at a Tertiary Hospital in Colombia: A Clinical and Microbiological Profile
por: Vallejo, Marta, et al.
Publicado: (2019)

Keep on Taking the Tablets?
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_knc7b3leg37ftfuf0k2la8aon6